 |
|
Trial Seeks 'Genetic Fingerprint' for Predicting Drug Effectiveness
October 04, 2007Cincinnati-University of Cincinnati (UC) physician-scientists believe identifying a genetic "fingerprint" could help predict which specific therapies will be most effective for patients with gastric cancer.
Syed Ahmad, MD, is leading a national, phase-2 trial to test the effectiveness of combined chemotherapy and radiation therapy given to patients with gastric cancer before surgery. His team will also collect biological samples in an attempt to obtain genetic data that could be used to formulate targeted therapies.
Previous studies have established that either chemotherapy or radiation therapy after surgery can improve patient survival compared with surgery alone. Overall survival rates, however, remain low-with 20 to 30 percent of American patients surviving more than five years after treatment.
"Everyone agrees that without surgery, gastric cancer in not curable, and numerous studies have shown a benefit to follow-up therapy with either chemotherapy or radiation therapy," says Ahmad, assistant professor of surgery at UC and principal investigator of the trial.
"The problem is you can't give both radiation therapy and chemotherapy after surgery-it's too toxic and patients can't tolerate it," he says. "But you can give it before surgery when patients are healthiest."
This trial addresses what Ahmad calls the "future of cancer therapy": targeted drug regimens, based on the characteristics of a patient's specific tumor.
His goal is to identify a genetic "fingerprint" that could help predict whether patients will respond to therapy, and then identify drugs to address the specific molecular characteristics of that patient's tumor.
"Right now treatment is based on the assumption that site-based cancers are all the same, so every patient who has stage-3 gastric cancer will get the same chemotherapy drugs," Ahmad explains. "But the reality is that every cancer has a different expression of hormones, growth factors and genetic factors that must be addressed individually."
The UC-led national team is looking for about 70 patients across the United States with up to stage-3 gastric cancer to participate in the trial.
Prior to surgery, all study participants will have a biopsy to set baseline standards for genetic testing to determine which patients have a complete response to the multi-treatment therapy. Participants will receive daily doses of the platinum-containing drug oxaliplatin (ox-AL'-ih-plah-tin, marketed as Eloxatin) for six to eight weeks.
Approved by the Food and Drug Administration, oxaliplatin is currently used to treat advanced colorectal cancer. Studies have shown the drug has fewer toxicity complications compared with other therapies.
After six weeks of chemotherapy, the patient will get five consecutive days of three-dimensional, external-beam radiation therapy. Patients will be reevaluated two to three weeks after radiation to determine if they are eligible for surgery. Those who are suitable will have another tissue biopsy after surgery.
Researchers will compare pre- and post-surgery tissue samples to obtain the genetic data necessary to establish associations between molecular markers and drug resistance, with the goal of reducing toxicity associated with chemotherapeutic agents and improving patient survival.
University of Cincinnati
"Everyone agrees that without surgery, gastric cancer in not curable, and numerous studies have shown a benefit to follow-up therapy with either chemotherapy or radiation therapy," says Ahmad, assistant professor of surgery at UC and principal investigator of the trial.
"The problem is you can't give both radiation therapy and chemotherapy after surgery-it's too toxic and patients can't tolerate it," he says. "But you can give it before surgery when patients are healthiest."
This trial addresses what Ahmad calls the "future of cancer therapy": targeted drug regimens, based on the characteristics of a patient's specific tumor.
His goal is to identify a genetic "fingerprint" that could help predict whether patients will respond to therapy, and then identify drugs to address the specific molecular characteristics of that patient's tumor.
"Right now treatment is based on the assumption that site-based cancers are all the same, so every patient who has stage-3 gastric cancer will get the same chemotherapy drugs," Ahmad explains. "But the reality is that every cancer has a different expression of hormones, growth factors and genetic factors that must be addressed individually."
The UC-led national team is looking for about 70 patients across the United States with up to stage-3 gastric cancer to participate in the trial.
Prior to surgery, all study participants will have a biopsy to set baseline standards for genetic testing to determine which patients have a complete response to the multi-treatment therapy. Participants will receive daily doses of the platinum-containing drug oxaliplatin (ox-AL'-ih-plah-tin, marketed as Eloxatin) for six to eight weeks.
Approved by the Food and Drug Administration, oxaliplatin is currently used to treat advanced colorectal cancer. Studies have shown the drug has fewer toxicity complications compared with other therapies.
After six weeks of chemotherapy, the patient will get five consecutive days of three-dimensional, external-beam radiation therapy. Patients will be reevaluated two to three weeks after radiation to determine if they are eligible for surgery. Those who are suitable will have another tissue biopsy after surgery.
Researchers will compare pre- and post-surgery tissue samples to obtain the genetic data necessary to establish associations between molecular markers and drug resistance, with the goal of reducing toxicity associated with chemotherapeutic agents and improving patient survival.
University of Cincinnati
Chemotherapy News and Current Chemotherapy Events RSSInternational team reveals first prognosticator of survival in aggressive cancer
The tumor suppressor gene pRb2/p130 may provide the first independent prognostic biomarker in cases of soft tissue sarcoma (STS).
NC State Is First University in Nation to Offer Canine Bone Marrow Transplants
Dogs suffering from lymphoma will be able to receive the same type of medical treatment as their human counterparts, as North Carolina State University becomes the first university in the nation to offer canine bone marrow transplants in a clinical setting.
New nano device detects immune system cell signaling
Scientists have detected previously unnoticed chemical signals that individual cells in the immune system use to communicate with each other over short distances.
Barrow researchers identify a new approach to detect the early progression of brain tumors
Researchers at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center recently participated in a pilot study with the Montreal Neurological Institute that suggests a certain type of MRI scanning can detect when a patient is failing brain tumor treatment before symptoms appear.
Variation of normal protein could be key to resistance to common cancer drug
Researchers at the Moores Cancer Center at the University of California, San Diego (UC SD) in La Jolla have found evidence explaining why a common chemotherapy drug, cisplatin, may not always work for every cancer patient. They have shown that when a variant version of a key protein that normally causes cell death is active, patients may be resistant to the cancer-killing drug.
Normalizing tumor vessels to improve cancer therapy
Chemotherapy drugs often never reach the tumors they're intended to treat, and radiation therapy is not always effective, because the blood vessels feeding the tumors are abnormal-"leaky and twisty" in the words of the late Judah Folkman, MD, founder of the Vascular Biology program at Children's Hospital Boston.
UTMB researchers test new vaccine to fight multiple influenza strains
A universal vaccine effective against several strains of influenza has passed its first phase of testing, according to Dr. Christine Turley of the University of Texas at Galveston.
Drugs to inhibit blood vessel growth show promise in rat model of deadly brain tumor
In a landmark study, Medical College of Wisconsin researchers in Milwaukee report that drugs used to inhibit a specific fatty acid in rat brains with glioblastoma-like tumors not only reduced new blood vessel growth and tumor size dramatically, but also prolonged survival. The study is the featured cover story of the August, 2008 Journal of Cerebral Blood Flow & Metabolism.
Bowel cancer indicator should lead to better treatment
STEM cell scientists have developed a more accurate way of identifying aggressive forms of bowel cancer, which should eventually lead to better treatment and survival rates.
Stem cell indicator for bowel cancer should lead to better survival rates
Stem cell scientists have developed a more accurate way of identifying aggressive forms of bowel cancer, which should eventually lead to better treatment and survival rates. Bowel cancer is the third most common cancer in the UK.
More Chemotherapy News Articles
 | Pharmacotherapy: A Pathophysiologic Approach by Joseph T. DiPiro, Robert L. Talbert, Gary C. Yee, Gary R. Matzke, Barbara G. Wells, L. Michael Posey The benchmark evidence-based pharmacotherapy text-now in full color! Additional chapters are available online When it comes to helping you develop a mastery of evidence-based medicine for optimal patient outcomes, no book can match Pharmacotherapy: A Pathophysiologic Approach. Like the discipline it covers, the scope of this trusted resource goes beyond drug indications and dosages to... |
 | Arriving at Your Own Door: 108 Lessons in Mindfulness by Jon Kabat-zinn Mindfulness opens us up to the possibility of being fully human as we are, and of expressing the humane in our way of being. Mindlessness de facto closes us up and denies us the fullness of our being alive. This book may on the surface appear to be merely another offering in the genre of daily readings. But deep within these 108 selections lie messages of profound wisdom in a contemporary and... |
 | Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (Essential Psychopharmacology Series) by Stephen M. Stahl Essential. Trusted. Indispensable. Stahl's Essential Psychopharmacology has established itself as the preeminent source of education and information in its field. This much-expanded third edition relies on advances in neurobiology and recent clinical developments to explain the concepts underlying drug treatment of psychiatric disorders. In addition to redrawn art, an improved and more... |
 | The Clinical Drug Therapy: Rationales for Nursing Practice (Field Guide Series) by Anne Collins Abrams, Sandra Smith Pennington, Carol Barnett Lammon This popular core nursing pharmacology textbook provides unique coverage of nursing interventions for drug therapy with related rationales. Highly praised for its organized and readable presentation, the text explains the "why" behind each nursing action and emphasizes how drugs work differently in different patients. New to the Eighth Edition are case studies integrated into each chapter with... |
 | Drug Therapy in Nursing by Diane S Aschenbrenner, Samantha J Venable This text presents a totally nursing-focused framework for teaching and learning nursing pharmacology, and "places the patient" at the center of all drug and drug administration decisions and considerations. The book presents core drug knowledge using prototypes of different drug classes and emphasizes core patient variables that influence the patient's response to therapy. Features include... |
 | Coming to Our Senses: Healing Ourselves and the World Through Mindfulness by Jon Kabat-zinn Ten years ago, Jon Kabat-Zinn changed the way we thought about awareness in everyday life with his now-classic introduction to mindfulness, Wherever You Go, There You Are. Now, with Coming to Our Senses, he provides the definitive book for our time on the connection between mindfulness and our physical and spiritual well-being. With scientific rigor, poetic deftness, and compelling personal... |
 | Pharmacotherapy Handbook (PHARMACOTHERAPY HANDBOOK) by Barbara G. Wells, Joseph T. DiPiro, Terry L. Schwinghammer, Cindy Hamilton The second edition of the Pharmacotherapy Handbook provides readers with a portable, readable guide that is integral to any clinical setting. Bold-face type highlights drug names when they first appear and in all closing information. The book's bulleted format helps readers find the information they need immediately. This updated book was designed as a companion text for the fourth edition... |
 | Applied Therapeutics: The Clinical Use of Drugs (APPLIED THERAPEUTICS (KODA-KIMBLE)) by Mary Anne Koda-Kimble Using a case-based approach, the Ninth Edition of Applied Therapeutics: The Clinical Use of Drugs enables students to master the fundamentals of drug therapeutics. All the contributors are leading clinicians with many years of evidence-based care. As students progress through the text, they will learn the basics of common diseases and disorders and develop practical problem-solving skills for... |
 | Acid-Base, Fluids, and Electrolytes Made Ridiculously Simple (MedMaster Series) by Richard Arthur Preston A brief, highly readable book providing the clinician with a straightforward approach to solving even the most complex, acid-base, fluid, and electrolyte problems. Useful to medical students, interns and residents, nurses responsible for IV fluid therapy, and first year nephrology... |
 | Mental Disorders, Medications, and Clinical Social Work by Sonia G. Austrian Written for social workers by a social worker, Mental Disorders, Medications, and Clinical Social Work discusses the etiology, epidemiology, assessment, and intervention planning for common mental disorders. Looking at disorders from an ecosystems perspective, Austrian goes beyond a linear classification approach and DSM-IV-TR categories and encourages social workers to analyze the internal and... |
| © 2008 BrightSurf.com |